aspartic acid has been researched along with Diarrhea in 15 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
Excerpt | Relevance | Reference |
---|---|---|
"In a previous trial in which methotrexate and N-phosphonacetyl-L-aspartate (PALA) were used to modulate 5-fluorouracil (5-FU), four of six patients could not tolerate treatment at the 600 mg/m2 5-FU dose level because of mucositis, diarrhea, and a decrease in performance status." | 3.68 | Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin. ( Colofiore, J; Kemeny, N; Martin, D; Sawyer, R; Schneider, A; Seiter, K; Williams, L, 1993) |
"In 2594 patients with complete adverse event (AE) data, the incidence of grade 3 or greater 5FU-AEs in DPYD*2A, I560S, and D949V carriers were 22/25 (88." | 2.79 | DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). ( Alberts, SR; Berenberg, JL; Diasio, RB; Goldberg, RM; Lee, AM; Pavey, E; Sargent, DJ; Shi, Q; Sinicrope, FA, 2014) |
"Diarrhea was dose-limiting; 6/13 patients had grade II or worse diarrhea at 2,600 mg/m2." | 2.68 | Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer. ( Brennan, J; Hageboutros, A; Hudes, GR; LaCreta, FP; McAleer, C; Newman, EM; O'Dwyer, PJ; Ozols, RF; Rogatko, A, 1995) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 8 (53.33) | 18.7374 |
1990's | 5 (33.33) | 18.2507 |
2000's | 1 (6.67) | 29.6817 |
2010's | 1 (6.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lee, AM | 1 |
Shi, Q | 1 |
Pavey, E | 1 |
Alberts, SR | 1 |
Sargent, DJ | 1 |
Sinicrope, FA | 1 |
Berenberg, JL | 1 |
Goldberg, RM | 1 |
Diasio, RB | 1 |
Tabrizi, SJ | 1 |
Blamire, AM | 1 |
Manners, DN | 1 |
Rajagopalan, B | 1 |
Styles, P | 1 |
Schapira, AH | 1 |
Warner, TT | 1 |
Doyle, JA | 1 |
Perry, HO | 1 |
Rubin, J | 1 |
Moertel, CG | 1 |
Ardalan, B | 2 |
Jamin, D | 1 |
Jayaram, HN | 1 |
Presant, CA | 1 |
Kurzrock, R | 1 |
Yap, BS | 1 |
Plager, C | 1 |
Papdopoulos, N | 1 |
Benjamin, RS | 1 |
Valdivieso, M | 1 |
Bodey, GP | 1 |
Creagan, ET | 1 |
O'Connell, MJ | 1 |
Kovach, JS | 1 |
Gralla, RJ | 1 |
Casper, ES | 1 |
Natale, RB | 1 |
Yagoda, A | 1 |
Young, CW | 1 |
Meropol, NJ | 1 |
Creaven, PJ | 1 |
Petrelli, NJ | 1 |
Leichman, CG | 1 |
Fleming, TR | 1 |
Muggia, FM | 1 |
Tangen, CM | 1 |
Doroshow, JH | 1 |
Meyers, FJ | 1 |
Holcombe, RF | 1 |
Weiss, GR | 1 |
Mangalik, A | 1 |
Hageboutros, A | 1 |
Rogatko, A | 1 |
Newman, EM | 1 |
McAleer, C | 1 |
Brennan, J | 1 |
LaCreta, FP | 1 |
Hudes, GR | 1 |
Ozols, RF | 1 |
O'Dwyer, PJ | 1 |
Witteman, JC | 1 |
Grobbee, DE | 1 |
Derkx, FH | 1 |
Bouillon, R | 1 |
de Bruijn, AM | 1 |
Hofman, A | 1 |
Seiter, K | 1 |
Kemeny, N | 1 |
Martin, D | 1 |
Schneider, A | 1 |
Williams, L | 1 |
Colofiore, J | 1 |
Sawyer, R | 1 |
Erlichman, C | 1 |
Strong, JM | 1 |
Wiernik, PH | 1 |
McAvoy, LM | 1 |
Cohen, MH | 1 |
Levine, AS | 1 |
Hubbard, SM | 1 |
Chabner, BA | 1 |
Cooney, DA | 1 |
Yavelow, J | 1 |
Zlotoff, R | 1 |
Bergenstal, R | 1 |
Burg, A | 1 |
Morrison, R | 1 |
Fleischman, R | 1 |
Prosky, L | 1 |
O'Dell, RG | 1 |
1 review available for aspartic acid and Diarrhea
Article | Year |
---|---|
Metastatic colorectal cancer: advances in biochemical modulation and new drug development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisplatin; Colorectal Neoplasms; Diar | 1995 |
5 trials available for aspartic acid and Diarrhea
Article | Year |
---|---|
DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study.
Topics: Adenosine Triphosphate; Aspartic Acid; Brain; Choline; Creatine; Diarrhea; Dietary Supplements; Dose | 2003 |
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chem | 1995 |
Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspart | 1995 |
Reduction of blood pressure with oral magnesium supplementation in women with mild to moderate hypertension.
Topics: Administration, Oral; Adult; Aged; Aspartic Acid; Blood Pressure; Body Weight; Diarrhea; Double-Blin | 1994 |
9 other studies available for aspartic acid and Diarrhea
Article | Year |
---|---|
Treatment of psoriasis with N-phosphonacetyl-L-aspartate.
Topics: Adult; Aged; Arthritis; Aspartic Acid; Diarrhea; Drug Eruptions; Female; Follow-Up Studies; Humans; | 1984 |
Phase I study of continuous-infusion PALA and 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Asparti | 1984 |
Phase II evaluation of PALA in patients with refractory metastatic sarcomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Bone Neoplasms; Diarrhea; Drug Evaluati | 1984 |
A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
Topics: Alanine; Aspartic Acid; Diarrhea; Digestive System Neoplasms; Drug Administration Schedule; Drug Eva | 1983 |
Phase I trial of PALA.
Topics: Antineoplastic Agents; Aspartic Acid; Brain Diseases; Diarrhea; Dose-Response Relationship, Drug; Ga | 1980 |
Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Diarrhea; Drug Synergism | 1993 |
Phase I trial of N-(phosphonacetyl)-L-aspartate.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Colonic Neoplasms; Diarrhea; Drug Eruptions; Drug Evaluation | 1979 |
Azotomycin--toxicologic, biochemical and pharmacologic studies in mice.
Topics: Animals; Antibiotics, Antineoplastic; Asparagine; Aspartate Aminotransferases; Aspartic Acid; Ataxia | 1974 |
Effects of cyclamate and food restriction on various metabolites in the rat.
Topics: Animals; Aspartic Acid; Blood Proteins; Body Weight; Carbon Dioxide; Carbon Isotopes; Cholesterol; C | 1972 |